Jack Hoppin, Ph.D., Co-Founder and Managing Director of inviCRO, LLC, joins the Board of Trustees of the World Molecular Imaging Society (WMIS)

Continued close alliance between inviCRO and WMIS includes WMIS sponsorship and President Anna Wu's Keynote Presentation at inviCRO's Upcoming *Translational Imaging Symposium*

BOSTON, MA (August 26, 2014) – inviCRO, LLC, a Boston-based leading service provider of imaging service solutions and imaging analysis software for research and drug development, is pleased to announce the selection of co-founder and Managing Director Jack Hoppin, Ph.D., to the Board of Trustees of the World Molecular Imaging Society (WMIS). Dr. Hoppin's participation on the Board is effective immediately, where he will serve for a 3-year term.

WMIS is an international scientific organization dedicated to the understanding of biology and medicine through multimodal *in vivo* imaging of cellular and molecular events involved in normal and pathologic processes and utilization of quantitative molecular imaging in patient care. It is a leading organization in the pre-clinical molecular imaging field representing stakeholders from industry, the research community as well as the growing development and education of translational imaging scientists.

Dr. Hoppin, a thought-leader in the molecular imaging research and drug development community, brings 15+ years in experience in the design, development and commercialization of pre-clinical instrumentation, analytical software and imaging-based assays. Dr. Hoppin's efforts have directly contributed to over $100 million in sales related to pre-clinical imaging instrumentation, software, and services. He will contribute his extensive multi-disciplinary experience, with a key focus on imaging bioinformatics in drug development and discovery, to the WMIS Board. "I'm honored to have been chosen to join the Board of WMIS, an organization that has always provided strong leadership and guidance for the translational molecular imaging industry," says Dr. Hoppin. "With the increasing complexity in multi-modal, multi-resolution imaging and the pressures of time-to-market and cost control, the need for imaging bioinformatics is greater than ever. On behalf of our interdisciplinary team at inviCRO, I'm glad to be able to share our insights to help contribute to WMIS's impressive leadership team."

The close partnership between the two organizations is further extended by WMIS's attendance and sponsorship of inviCRO's upcoming Translational Imaging Symposium. The event, which will take place in the Innovation District in Boston, MA on October 9, 2014, will feature leaders in translational molecular imaging presenting on the latest advances and emerging global trends in the field.

"We are thrilled that Jack will be joining WMIS's Board as he brings significant insight into the changing and complex needs and strategies in leveraging imaging and bioinformatics to change the paradigm of drug development and discovery", says WMIS President Anna Wu, Ph.D. "We look forward to a close collaboration with inviCRO, including our sponsorship and my speaking at the upcoming *Translational Imaging Symposium*, where best-of-breed techniques in molecular imaging can be shared by many leaders in the field". Dr. Wu will be delivering the symposium's keynote address, titled "*ImmunoPET imaging of tumors and immune responses*".

In addition to her role as President of WMIS, Dr. Wu is a Professor and Vice Chair in the Department of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA, Los Angeles, CA.

She also holds an appointment as Professor in the Department of Pathology and Laboratory Medicine, and serves as Co-Associate Director of the Crump Institute for Molecular Imaging and Director of the Cancer Molecular Imaging Program in the Jonsson Comprehensive Cancer Center at UCLA. Dr. Wu is also a Co-Founder and Chief Scientific Advisor to ImaginAb, Inc., an LA-based startup company which develops and commercializes engineered antibodies for clinical imaging in cancer and other diseases.

inviCRO's collaboration with WMIS exemplifies inviCRO's increasing presence as a leading imaging services and software provider for research and drug development. inviCRO's latest imaging services and imaging software solutions, will be exhibiting in Booth #501 at the upcoming World Molecular Imaging Congress, WMIS's annual conference in Seoul, Korea, September 17 - 20, 2014.

About inviCRO:

inviCRO, LLC was founded with a mission of improving the value of imaging in drug discovery and development. The company provides a full range of imaging services and software solutions including image research services, custom data analysis, and software programs for image data management and high-throughput image processing. inviCRO's key software platforms include VivoQuant™, a complete post-processing suite, and iPACS®, an imaging study management platform, are industry-leading solutions used extensively by pre-clinical imaging facilities and in translation imaging in the pharmaceutical industry. The experienced team of 45+ research scientists at inviCRO possesses unique capabilities in imaging physics, advanced biostatistics, multi-dimensional image processing, and software development, as well as an intimate understanding of imaging systems, agents, and animal models. inviCRO has managed and/or processed more than 425 research imaging trials since 2008. Their software products are used in more than 125 laboratories worldwide, including 13 of the top 25 pharmaceutical companies. In addition to their multi-modality imaging facility in Boston's Innovation District, inviCRO's services are delivered through a network of validated partners highlighted by the co-managed cyclotron facility at the Translational Imaging Center (inviCRO, MPI Research, 3DI).

For more information, please contact:

Kat Ramey,
inviCRO, LLC.
T. +1.617-904-2117
E. kramey@invicro.com
www.invicro.com